Purpose: To evaluate the effects of repeated intravitreal dexamethasone implant. Methods: We reviewed the charts of 12 patients with diabetic macular edema, who received at least 2 intravitreal Ozurdex (0.7 mg) on an "as needed" basis. Main outcome measures included changes in best-corrected visual acuity, central macular thickness, retreatment interval, and incidence of side effects. Results: A total of 15 eyes of 12 patients (6 men, 6 women; mean age 62 +/- 12 years) were included. Retreatment was judged necessary after mean of 7.8 +/- 4.1 months from the first Ozurdex (median, 6 months) (15 of 15 eyes), mean of 4.8 +/- 0.9 months from the second Ozurdex (median, 5 months) (7 of 15 eyes), mean of 5.3 +/- 1.5 months from the third Ozurdex (median, 5 months) (3 of 15 eyes), and mean of 5.6 +/- 2 months from the fourth Ozurdex (median, 5 months) (3 of 15 eyes). Mean baseline best-corrected visual acuity was 0.67 +/- 0.33 logMAR in the overall diabetic macular edema population; it significantly improved to 0.53 +/- 0.31 logMAR after mean of 40.9 +/- 18.2 days from the first Ozurdex (peaking efficacy) (P < 0.001), to 0.53 +/- 0.29 logMAR after mean of 34.4 +/- 9.0 days from the second Ozurdex (peaking efficacy) (P < 0.003), and stabilized to 0.62 +/- 0.26 logMAR after mean of 29.8 +/- 12.1 days from the third Ozurdex (peaking efficacy) (P = 0.05), to 0.5 +/- 0.26 logMAR after mean of 36.3 +/- 3.2 days from the fourth Ozurdex (peaking efficacy) (P = 0.2), and to 0.50 +/- 0.26 logMAR after mean of 37.0 +/- 2.6 days from the fifth Ozurdex (peaking efficacy) (P = 0.2). Mean baseline central macular thickness significantly decreased from 546 +/- 139 mu m to 292 +/- 43 mu m at 39.4 +/- 17.9 days from the first Ozurdex (peaking efficacy) (P < 0.001), to 297 +/- 47 mu m at 33 +/- 9.4 days from the second Ozurdex (peaking efficacy) (P < 0.001), to 293 +/- 22 mu m at 29.8 +/- 12.1 days from the third Ozurdex (peaking efficacy) (P = 0.01), and stabilized to 309 +/- 35 mu m at 36.3 +/- 3.2 days from the fourth Ozurdex (peaking efficacy) (P = 0.1), and to 295 +/- 7 mu m at 37.0 +/- 2.6 days from the fifth Ozurdex (peaking efficacy) (P = 0.1). No serious adverse events were observed; three eyes developed a transient intraocular pressure increase, and cataract was extracted in one eye. Conclusion: Repeated intravitreal Ozurdex on an "as needed" basis with a variable retreatment interval may produce long-term clinically meaningful benefits in the treatment of diabetic macular edema, without other significant side effects than expected after intraocular corticosteroid treatment.

Purpose: To evaluate the effects of repeated intravitreal dexamethasone implant. Methods: We reviewed the charts of 12 patients with diabetic macular edema, who received at least 2 intravitreal Ozurdex (0.7 mg) on an "as needed" basis. Main outcome measures included changes in best-corrected visual acuity, central macular thickness, retreatment interval, and incidence of side effects. Results: A total of 15 eyes of 12 patients (6 men, 6 women; mean age 62 +/- 12 years) were included. Retreatment was judged necessary after mean of 7.8 +/- 4.1 months from the first Ozurdex (median, 6 months) (15 of 15 eyes), mean of 4.8 +/- 0.9 months from the second Ozurdex (median, 5 months) (7 of 15 eyes), mean of 5.3 +/- 1.5 months from the third Ozurdex (median, 5 months) (3 of 15 eyes), and mean of 5.6 +/- 2 months from the fourth Ozurdex (median, 5 months) (3 of 15 eyes). Mean baseline best-corrected visual acuity was 0.67 +/- 0.33 logMAR in the overall diabetic macular edema population; it significantly improved to 0.53 +/- 0.31 logMAR after mean of 40.9 +/- 18.2 days from the first Ozurdex (peaking efficacy) (P < 0.001), to 0.53 +/- 0.29 logMAR after mean of 34.4 +/- 9.0 days from the second Ozurdex (peaking efficacy) (P < 0.003), and stabilized to 0.62 +/- 0.26 logMAR after mean of 29.8 +/- 12.1 days from the third Ozurdex (peaking efficacy) (P = 0.05), to 0.5 +/- 0.26 logMAR after mean of 36.3 +/- 3.2 days from the fourth Ozurdex (peaking efficacy) (P = 0.2), and to 0.50 +/- 0.26 logMAR after mean of 37.0 +/- 2.6 days from the fifth Ozurdex (peaking efficacy) (P = 0.2). Mean baseline central macular thickness significantly decreased from 546 +/- 139 mu m to 292 +/- 43 mu m at 39.4 +/- 17.9 days from the first Ozurdex (peaking efficacy) (P < 0.001), to 297 +/- 47 mu m at 33 +/- 9.4 days from the second Ozurdex (peaking efficacy) (P < 0.001), to 293 +/- 22 mu m at 29.8 +/- 12.1 days from the third Ozurdex (peaking efficacy) (P = 0.01), and stabilized to 309 +/- 35 mu m at 36.3 +/- 3.2 days from the fourth Ozurdex (peaking efficacy) (P = 0.1), and to 295 +/- 7 mu m at 37.0 +/- 2.6 days from the fifth Ozurdex (peaking efficacy) (P = 0.1). No serious adverse events were observed; three eyes developed a transient intraocular pressure increase, and cataract was extracted in one eye. Conclusion: Repeated intravitreal Ozurdex on an "as needed" basis with a variable retreatment interval may produce long-term clinically meaningful benefits in the treatment of diabetic macular edema, without other significant side effects than expected after intraocular corticosteroid treatment.

REPEATED INTRAVITREAL DEXAMETHASONE IMPLANT (OZURDEX) FOR DIABETIC MACULAR EDEMA

QUERQUES , GIUSEPPE;BANDELLO , FRANCESCO
2015

Abstract

Purpose: To evaluate the effects of repeated intravitreal dexamethasone implant. Methods: We reviewed the charts of 12 patients with diabetic macular edema, who received at least 2 intravitreal Ozurdex (0.7 mg) on an "as needed" basis. Main outcome measures included changes in best-corrected visual acuity, central macular thickness, retreatment interval, and incidence of side effects. Results: A total of 15 eyes of 12 patients (6 men, 6 women; mean age 62 +/- 12 years) were included. Retreatment was judged necessary after mean of 7.8 +/- 4.1 months from the first Ozurdex (median, 6 months) (15 of 15 eyes), mean of 4.8 +/- 0.9 months from the second Ozurdex (median, 5 months) (7 of 15 eyes), mean of 5.3 +/- 1.5 months from the third Ozurdex (median, 5 months) (3 of 15 eyes), and mean of 5.6 +/- 2 months from the fourth Ozurdex (median, 5 months) (3 of 15 eyes). Mean baseline best-corrected visual acuity was 0.67 +/- 0.33 logMAR in the overall diabetic macular edema population; it significantly improved to 0.53 +/- 0.31 logMAR after mean of 40.9 +/- 18.2 days from the first Ozurdex (peaking efficacy) (P < 0.001), to 0.53 +/- 0.29 logMAR after mean of 34.4 +/- 9.0 days from the second Ozurdex (peaking efficacy) (P < 0.003), and stabilized to 0.62 +/- 0.26 logMAR after mean of 29.8 +/- 12.1 days from the third Ozurdex (peaking efficacy) (P = 0.05), to 0.5 +/- 0.26 logMAR after mean of 36.3 +/- 3.2 days from the fourth Ozurdex (peaking efficacy) (P = 0.2), and to 0.50 +/- 0.26 logMAR after mean of 37.0 +/- 2.6 days from the fifth Ozurdex (peaking efficacy) (P = 0.2). Mean baseline central macular thickness significantly decreased from 546 +/- 139 mu m to 292 +/- 43 mu m at 39.4 +/- 17.9 days from the first Ozurdex (peaking efficacy) (P < 0.001), to 297 +/- 47 mu m at 33 +/- 9.4 days from the second Ozurdex (peaking efficacy) (P < 0.001), to 293 +/- 22 mu m at 29.8 +/- 12.1 days from the third Ozurdex (peaking efficacy) (P = 0.01), and stabilized to 309 +/- 35 mu m at 36.3 +/- 3.2 days from the fourth Ozurdex (peaking efficacy) (P = 0.1), and to 295 +/- 7 mu m at 37.0 +/- 2.6 days from the fifth Ozurdex (peaking efficacy) (P = 0.1). No serious adverse events were observed; three eyes developed a transient intraocular pressure increase, and cataract was extracted in one eye. Conclusion: Repeated intravitreal Ozurdex on an "as needed" basis with a variable retreatment interval may produce long-term clinically meaningful benefits in the treatment of diabetic macular edema, without other significant side effects than expected after intraocular corticosteroid treatment.
Purpose: To evaluate the effects of repeated intravitreal dexamethasone implant. Methods: We reviewed the charts of 12 patients with diabetic macular edema, who received at least 2 intravitreal Ozurdex (0.7 mg) on an "as needed" basis. Main outcome measures included changes in best-corrected visual acuity, central macular thickness, retreatment interval, and incidence of side effects. Results: A total of 15 eyes of 12 patients (6 men, 6 women; mean age 62 +/- 12 years) were included. Retreatment was judged necessary after mean of 7.8 +/- 4.1 months from the first Ozurdex (median, 6 months) (15 of 15 eyes), mean of 4.8 +/- 0.9 months from the second Ozurdex (median, 5 months) (7 of 15 eyes), mean of 5.3 +/- 1.5 months from the third Ozurdex (median, 5 months) (3 of 15 eyes), and mean of 5.6 +/- 2 months from the fourth Ozurdex (median, 5 months) (3 of 15 eyes). Mean baseline best-corrected visual acuity was 0.67 +/- 0.33 logMAR in the overall diabetic macular edema population; it significantly improved to 0.53 +/- 0.31 logMAR after mean of 40.9 +/- 18.2 days from the first Ozurdex (peaking efficacy) (P < 0.001), to 0.53 +/- 0.29 logMAR after mean of 34.4 +/- 9.0 days from the second Ozurdex (peaking efficacy) (P < 0.003), and stabilized to 0.62 +/- 0.26 logMAR after mean of 29.8 +/- 12.1 days from the third Ozurdex (peaking efficacy) (P = 0.05), to 0.5 +/- 0.26 logMAR after mean of 36.3 +/- 3.2 days from the fourth Ozurdex (peaking efficacy) (P = 0.2), and to 0.50 +/- 0.26 logMAR after mean of 37.0 +/- 2.6 days from the fifth Ozurdex (peaking efficacy) (P = 0.2). Mean baseline central macular thickness significantly decreased from 546 +/- 139 mu m to 292 +/- 43 mu m at 39.4 +/- 17.9 days from the first Ozurdex (peaking efficacy) (P < 0.001), to 297 +/- 47 mu m at 33 +/- 9.4 days from the second Ozurdex (peaking efficacy) (P < 0.001), to 293 +/- 22 mu m at 29.8 +/- 12.1 days from the third Ozurdex (peaking efficacy) (P = 0.01), and stabilized to 309 +/- 35 mu m at 36.3 +/- 3.2 days from the fourth Ozurdex (peaking efficacy) (P = 0.1), and to 295 +/- 7 mu m at 37.0 +/- 2.6 days from the fifth Ozurdex (peaking efficacy) (P = 0.1). No serious adverse events were observed; three eyes developed a transient intraocular pressure increase, and cataract was extracted in one eye. Conclusion: Repeated intravitreal Ozurdex on an "as needed" basis with a variable retreatment interval may produce long-term clinically meaningful benefits in the treatment of diabetic macular edema, without other significant side effects than expected after intraocular corticosteroid treatment.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/5997
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 49
  • ???jsp.display-item.citation.isi??? 44
social impact